May 14, 2025

Genomate Health Raises $2M, Enters US Market with Precision Oncology Clinical Decision Support Tool

May 14, 2025

Genomate Health, a spinoff from Hungarian medical technology firm Oncompass Medicine, said Monday that it has entered the US market and will begin offering its genomics-based precision oncology drug selection platform, a clinical decision support system.

Other Media Coverage

See all

How Vietnam is Leveraging AI to Reshape Healthcare

December 1, 2024

Read Article

Genomate Health Brings European Innovation and $2M in Investment to the United States

May 12, 2025

Read Article

Genomate Health Raises $2M, Enters US Market with Precision Oncology Clinical Decision Support Tool

May 13, 2025

Read Article

Other Resources

The Genomate® Report can be used and clinically interpreted only by physicians or other qualified healthcare professionals. Genomate® is a clinical decision support software and is not intended to diagnose, treat, cure, prevent, or mitigate any condition. None of the statements contained herein have been evaluated by the U.S. Food and Drug Administration. Learn more.